Skip to main content
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SNOA ISIN · US83558L2043 US Manufacturing
Open in API
Filings indexed 951 across all filing types
Latest filing 2020-07-10 Annual Report
Country US United States of America
Listing US SNOA

About Sonoma Pharmaceuticals, Inc.

https://sonomapharma.com/

Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and commercializes products based on its patented Microcyn® Technology, a stabilized hypochlorous acid (HOCl) platform. With over 20 years of experience, the company produces a range of prescription and over-the-counter solutions for advanced wound care, dermatology, animal health, and eye care. Its products are designed to manage various conditions by promoting healing and reducing the risk of infection. The portfolio serves healthcare professionals in settings like hospitals and nursing homes, as well as consumers for at-home use.

Recent filings

Filing Released Lang Actions
FORM10-K
Annual Report FY 2020
2020-07-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 24, 2020, by Sonoma Pharmaceuticals, Inc. It reports a material definitive agreement and completion of an asset sale transaction, including relocation of manufacturing and corporate functions. The content focuses on corporate operational changes and a specific asset purchase agreement, typical of current reports on significant corporate events. There are no financial statements or detailed financial performance data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, governance, or remuneration report. It is a regulatory filing reporting a material event, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-06-29 English
FORM 12B-25 (NT 10-K)
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the Form 10-K annual report for the period ended March 31, 2020, could not be filed on time due to the auditors requiring additional time to complete their audit. The document does not contain the actual 10-K report or financial data but is a notification about the delay in filing the 10-K. According to the 'MENU VS MEAL' rule, such a notification is not the report itself but an announcement related to the filing status. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-06-29 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated June 4, 2020, reporting the departure of an executive officer, Dr. Robert Northey, including details about his termination, separation agreement, and consulting agreement. The key content is about management changes, specifically the departure and appointment of officers. There are no financial statements or earnings data presented, nor is this a report of voting results or a regulatory compliance filing. The primary focus is on management changes, which aligns with the Board/Management Information category (MANG). The document length is 5849 characters, sufficient to contain substantive information about management changes rather than a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2020-06-04 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement (a license and distribution agreement) with a partner. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, voting result, or management change announcement. It is a regulatory filing to disclose a significant contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 5240 characters, which is sufficient to contain substantive information but does not constitute a full financial report or presentation.
2020-05-26 English
FORM 8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2020, by Sonoma Pharmaceuticals, Inc. It reports the entry into a material definitive agreement related to a loan under the Paycheck Protection Program (PPP). The content focuses on a financing event (loan proceeds received, terms of the loan, intended use, and potential forgiveness). There are no financial statements or comprehensive financial performance data included, nor is it an earnings release or management discussion. The document is a current report on a material event, specifically a financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is about 5,043 characters, which is consistent with a detailed 8-K filing on a financing event, not a brief announcement or a full annual or quarterly report.
2020-05-04 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.